Upcoming Financial Results Announcement by Celcuity Inc.
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company specializing in targeted oncology therapies, is gearing up for an important financial announcement. The company plans to release its financial results for the fourth quarter and the full year of 2024. Investors can look forward to this release, which will occur after the market closes on a scheduled date near the end of March 2025.
Conference Call and Webcast Details
As part of this announcement, Celcuity's management will be hosting a conference call accompanied by a webcast. The event will commence at 4:30 PM Eastern Time, the same day as the financial results release. This offers an opportunity for shareholders and interested parties to gain insights directly from the management regarding the company’s performance and strategic direction.
For those interested in participating, domestic callers can join the teleconference by dialing 1-800-717-1738, while international participants may dial 1-646-307-1865. Additionally, a live webcast will be accessible for those choosing to engage with the presentation online.
Highlights of Celcuity's Key Achievements
Celcuity continues to focus on innovative therapies for serious cancer conditions. Their leading candidate, gedatolisib, is currently in advanced clinical testing. This dual-action therapy is being evaluated for efficacy among various cancer types, including specific solid tumors. Recent trials, such as the VIKTORIA-1 study, exemplify the company's commitment to pioneering new treatment modalities.
Clinical Trials Overview
The VIKTORIA-1 study is particularly notable. It aims to assess the combination of gedatolisib and another established drug, fulvestrant, with an optional addition of palbociclib for patients diagnosed with advanced breast cancer. Furthermore, as the landscape of cancer treatment evolves, Celcuity is also initiating a new clinical trial, VIKTORIA-2, later this year, which will further investigate the application of gedatolisib alongside other therapeutic agents for first-line treatment in similar patient demographics.
Moreover, the ongoing CELC-G-201 trial is examining gedatolisib's potential when combined with darolutamide specifically for treating metastatic castration-resistant prostate cancer, underscoring Celcuity's broad therapeutic aspirations.
About Celcuity Inc.
Based in Minneapolis, Celcuity operates with a clear vision: to develop targeted therapies that transform cancer treatment and improve patient outcomes. Their pipeline not only focuses on delivering innovative solutions but also aims to address unmet medical needs in oncology.
Looking Ahead
As the web conference approaches, investors and analysts alike are eager to explore the updates that Celcuity will share, particularly regarding their clinical findings and financial performance. With promising results from ongoing studies and an engaged leadership team, the company is poised for a bright future.
Frequently Asked Questions
What financial results will Celcuity Inc. announce?
Celcuity Inc. will announce its financial results for the fourth quarter and full year of 2024.
When is the conference call scheduled?
The conference call is scheduled for 4:30 PM Eastern Time on the day of the financial announcement.
How can I participate in the teleconference?
Domestic participants can call 1-800-717-1738, while international callers should dial 1-646-307-1865.
What is Celcuity's lead therapeutic candidate?
Celcuity's lead candidate is gedatolisib, a potent inhibitor targeting both PI3K and mTOR pathways.
Where can I find more information about Celcuity?
Further information is available on Celcuity's official website.
